On August 28 (local time), Lilly announced that its blockbuster drug Tirzepatide (trade name: Mounjaro), a dual agonist of the GLP-1/GIP receptor, has been approved by the FDA for a new indication to reduce the risk of major adverse cardiovascular events (MACE, including CV death, non-fatal myocardial infarction, and non-fatal stroke) in patients with type 2 diabetes.
Telpotriol is the first GLP-1R/GIPR agonist approved for this indication.

The approval for this indication was based on topline results of cardiovascular outcomes from a head-to-head Phase 3 clinical trial (SURPASS-CVOT) comparing it to Eli Lilly's GLP-1 receptor agonist Trulicity (dulaglutide, trade name in China: Duyida, approved in China in 2019).
The SURPASS-CVOT study (Cardiovascular Outcomes Trial; NCT04255433/CTR20200498, co-led by Beijing Anzhen Hospital affiliated with Capital Medical University and Peking University People's Hospital in mainland China, with 22 other Chinese hospitals participating) is an event-driven, randomized, double-blind, head-to-head phase 3 trial designed to demonstrate that telpolide is non-inferior to dulaglutide in the risk of major adverse cardiovascular events (MACE-3, including the composite endpoint of cardiovascular death, heart attack, or stroke) in adults with type 2 diabetes and diagnosed atherosclerotic cardiovascular disease.
Telposide was first approved for marketing in the United States in May 2022. The drug is marketed under two brands: Mounjaro for the treatment of type 2 diabetes and Zepbound for long-term weight management and obstructive sleep apnea. According to Eli Lilly's 2026 interim report, global sales of Mounjaro and Zepbound were $18.6 billion and $9.1 billion, respectively, totaling $27.7 billion.

https://mp.weixin.qq.com/s?__biz=MzU5NjUwOTgyNg==&mid=2247726151&idx=3&sn=056331f2fddacbb7949a4b1c95a8f224&chksm=ff67dc108ed3e3a446a766e7adbf7572ff9d7d52edcfa4f3982ea0b415e386112507f6f2bb36&scene=126&sessionid=0#rd